SCHEMBL6056002

SCHEMBL6056002

[C]1=NNN(c2ccccn2)O1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLD1 Q13393 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 5/20 0.37
HSD17B10 Q99714 3/20 0.37
HTT P42858 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
GAA P10253 2/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPK1 P28482 2/20 0.36
POLB P06746 2/20 0.36
CYP1A2 P05177 2/20 0.36
EP300 Q09472 1/20 0.35
KAT2B Q92831 1/20 0.35
HPGD P15428 2/20 0.35
CRBN Q96SW2 1/20 0.35
CHEK1 O14757 1/20 0.35
AURKA O14965 1/20 0.35
DAPK3 O43293 1/20 0.35
JAK2 O60674 1/20 0.35
PRKD3 O94806 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5605890 0.66 PLD1 (0.41) PLD1SMN1; SMN2ALDH1A1HSD17B10HTT
SCHEMBL6237477 0.64 PLD1 (0.47) PLD1SMN1; SMN2ALDH1A1HSD17B10HTT
SCHEMBL5314104 0.62 PLD1 (0.49) PLD1SMN1; SMN2ALDH1A1HSD17B10HTT
SCHEMBL2646615 0.61 PLD1 (0.40) PLD1SMN1; SMN2ALDH1A1HSD17B10HTT
SCHEMBL1461902 0.61 SMN1; SMN2 (0.48) PLD1SMN1; SMN2ALDH1A1HSD17B10HTT
SCHEMBL20062878 0.60 SMN1; SMN2 (0.53) PLD1SMN1; SMN2ALDH1A1HSD17B10HTT
SCHEMBL30462881 0.59 SMN1; SMN2 (0.47) PLD1SMN1; SMN2ALDH1A1HSD17B10HTT
SCHEMBL5487603 0.59 SMN1; SMN2 (0.47) PLD1SMN1; SMN2ALDH1A1HSD17B10HTT
SCHEMBL21353591 0.59
SCHEMBL29857922 0.59 PLD1 (0.73) PLD1SMN1; SMN2ALDH1A1HSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060110782-A1 cycloalkyne compounds reacting with an azide moiety on a target biomolecule, by biochemical conjugation; for its application in vivo (on the cell surface or intracellularly) or in vitro (synthesis of peptides); labeling THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2006-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060110782-A1 cycloalkyne compounds reacting with an azide moiety on a target biomolecule, by biochemical conjugation; for its application in vivo (on the cell surface or intracellularly) or in vitro (synthesis of peptides); labeling PTMS, QPCT, DNPEP PLD1 1088/4885SMN1; SMN2 4810/4885ALDH1A1 3269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.